CrossBridge Bio Secures $10 Million Financing to Advance the Development of Next-Generation Dual-Payload ADC Therapies
November 04, 2024 08:00 AM Eastern Standard Time HOUSTON–(BUSINESS WIRE)–CrossBridge Bio, a biotechnology company pioneering dual-payload antibody-drug conjugates (ADCs) as targeted cancer therapies, today announced the closing of a $10 million seed financing led by…